Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas C Blevins

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Diabetes|August 18, 2015
Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetesJulio Rosenstock, Thomas C Blevins, Richard M Bergenstal, et al.
Diabetes, Obesity & Metabolism|August 17, 2018
Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 studyThomas C Blevins, Abhijit Barve, Bin Sun, et al.
Diabetes Care|August 13, 2014
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)John B Buse, Tina Vilsbøll, Jerry Thurman, et al.
Diabetes, Obesity & Metabolism|February 21, 2019
Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulinTina Vilsbøll, Thomas C Blevins, Esteban Jodar, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 17, 2022
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog<sup>®</sup>) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label StudyThomas C Blevins, Yaron Raiter, Bin Sun, et al.
Thyroid : Official Journal of the American Thyroid Association|May 10, 2014
Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodulesSylvie Beaudenon-Huibregtse, Erik K Alexander, Richard B Guttler, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 21, 2016
LONG-TERM NONOPERATIVE RATE OF THYROID NODULES WITH BENIGN RESULTS ON THE AFIRMA GENE EXPRESSION CLASSIFIERJennifer A Sipos, Thomas C Blevins, Heidi Chamberlain Shea, et al.
Diabetes Care|November 30, 2012
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover studyJulio Rosenstock, Richard M Bergenstal, Thomas C Blevins, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 2, 2011
Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoringThomas C Blevins, Bruce W Bode, Satish K Garg, et al.
The Journal of Clinical Endocrinology and Metabolism|November 2, 2013
Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: a randomized controlled clinical trialLowell R Schmeltz, Thomas C Blevins, Stephen L Aronoff, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Diabetes|August 18, 2015
Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetesJulio Rosenstock, Thomas C Blevins, Richard M Bergenstal, et al.
Diabetes, Obesity & Metabolism|August 17, 2018
Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 studyThomas C Blevins, Abhijit Barve, Bin Sun, et al.
Diabetes Care|August 13, 2014
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)John B Buse, Tina Vilsbøll, Jerry Thurman, et al.
Diabetes, Obesity & Metabolism|February 21, 2019
Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulinTina Vilsbøll, Thomas C Blevins, Esteban Jodar, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 17, 2022
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog<sup>®</sup>) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label StudyThomas C Blevins, Yaron Raiter, Bin Sun, et al.
Thyroid : Official Journal of the American Thyroid Association|May 10, 2014
Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodulesSylvie Beaudenon-Huibregtse, Erik K Alexander, Richard B Guttler, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 21, 2016
LONG-TERM NONOPERATIVE RATE OF THYROID NODULES WITH BENIGN RESULTS ON THE AFIRMA GENE EXPRESSION CLASSIFIERJennifer A Sipos, Thomas C Blevins, Heidi Chamberlain Shea, et al.
Diabetes Care|November 30, 2012
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover studyJulio Rosenstock, Richard M Bergenstal, Thomas C Blevins, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 2, 2011
Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoringThomas C Blevins, Bruce W Bode, Satish K Garg, et al.
The Journal of Clinical Endocrinology and Metabolism|November 2, 2013
Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: a randomized controlled clinical trialLowell R Schmeltz, Thomas C Blevins, Stephen L Aronoff, et al.
Pageof 3